Klebsiella pneumoniae
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
An encapsulated gut organism and a major cause of healthcare-associated infection, frequently carrying resistance genes. Hypervirulent strains can cause invasive community infection.
Infections
Urinary tract infection, pneumonia (including aspiration and ventilator-associated), bloodstream infection, liver abscess, wound infection.
Signs and symptoms
Urinary symptoms; pneumonia with fever, productive cough and shortness of breath; fever and rigors in bloodstream infection.
Antibiotic and antimicrobial resistance
Often carries ESBL genes (ESBL genes); KPC and other carbapenemases (carbapenemases) make it a prominent example of carbapenem-resistant Enterobacterales (CRE).
Treatment considerations
Guided by susceptibility testing. ESBL producers are usually treated with a carbapenem; carbapenemase producers need newer agents selected with infectious-diseases or pharmacy input.
Infection control and public health
Carbapenemase-producing strains require contact precautions and public-health notification in many jurisdictions.

Sources
- CDC. Klebsiella.
- CDC. ESBL-producing Enterobacterales.
- CDC. Carbapenem-resistant Enterobacterales (CRE).
- IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
- IDSA. Complicated Urinary Tract Infections guideline.
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.